Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neurofibromatoses | 13 | 2022 | 270 | 3.160 |
Why?
|
Neurofibromatosis 1 | 14 | 2023 | 538 | 2.790 |
Why?
|
Neurilemmoma | 10 | 2022 | 523 | 2.170 |
Why?
|
Neurofibromatosis 2 | 9 | 2022 | 364 | 1.680 |
Why?
|
Neurology | 6 | 2020 | 746 | 1.640 |
Why?
|
Brain Neoplasms | 17 | 2023 | 8804 | 1.310 |
Why?
|
Career Choice | 4 | 2020 | 744 | 1.300 |
Why?
|
Neurofibroma, Plexiform | 3 | 2022 | 68 | 1.250 |
Why?
|
Neurofibroma | 3 | 2022 | 97 | 1.160 |
Why?
|
Central Nervous System Neoplasms | 5 | 2022 | 870 | 0.810 |
Why?
|
Glioma | 6 | 2019 | 3295 | 0.740 |
Why?
|
Personnel Selection | 1 | 2021 | 194 | 0.720 |
Why?
|
Skin Neoplasms | 10 | 2022 | 5312 | 0.720 |
Why?
|
Internship and Residency | 5 | 2021 | 5618 | 0.680 |
Why?
|
Cultural Diversity | 1 | 2021 | 345 | 0.650 |
Why?
|
Interviews as Topic | 2 | 2021 | 2595 | 0.620 |
Why?
|
Meningioma | 4 | 2020 | 1196 | 0.570 |
Why?
|
Meningeal Neoplasms | 4 | 2020 | 1213 | 0.560 |
Why?
|
Rare Diseases | 6 | 2022 | 516 | 0.540 |
Why?
|
User-Computer Interface | 2 | 2021 | 1433 | 0.540 |
Why?
|
Quality Improvement | 3 | 2022 | 3748 | 0.530 |
Why?
|
Health Services | 1 | 2018 | 734 | 0.460 |
Why?
|
Diffusion Tensor Imaging | 1 | 2023 | 2188 | 0.460 |
Why?
|
Oculomotor Nerve Diseases | 1 | 2012 | 44 | 0.450 |
Why?
|
Lymphatic Diseases | 1 | 2014 | 330 | 0.450 |
Why?
|
Glioblastoma | 6 | 2021 | 3352 | 0.450 |
Why?
|
Managed Care Programs | 1 | 2018 | 990 | 0.440 |
Why?
|
Lymphoma, B-Cell | 2 | 2019 | 931 | 0.440 |
Why?
|
Neurofibrosarcoma | 2 | 2023 | 22 | 0.440 |
Why?
|
Hospice Care | 1 | 2018 | 618 | 0.420 |
Why?
|
Germ-Line Mutation | 2 | 2020 | 1730 | 0.410 |
Why?
|
Ataxia | 1 | 2012 | 282 | 0.400 |
Why?
|
Students, Medical | 2 | 2020 | 1764 | 0.390 |
Why?
|
Brain Diseases | 2 | 2019 | 1542 | 0.360 |
Why?
|
Isocitrate Dehydrogenase | 3 | 2019 | 832 | 0.350 |
Why?
|
Neurofibromin 2 | 2 | 2020 | 266 | 0.350 |
Why?
|
Immunotherapy, Adoptive | 3 | 2022 | 1030 | 0.330 |
Why?
|
Neurofibromin 1 | 2 | 2020 | 202 | 0.330 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2012 | 703 | 0.310 |
Why?
|
Molecular Targeted Therapy | 2 | 2018 | 2862 | 0.300 |
Why?
|
Length of Stay | 1 | 2018 | 6278 | 0.260 |
Why?
|
Chemotaxis, Leukocyte | 1 | 2007 | 712 | 0.250 |
Why?
|
Humans | 60 | 2023 | 715124 | 0.230 |
Why?
|
Chemokines | 1 | 2007 | 959 | 0.230 |
Why?
|
Quality of Health Care | 1 | 2018 | 4281 | 0.230 |
Why?
|
Lymph Nodes | 1 | 2014 | 3433 | 0.220 |
Why?
|
Lymphoma | 2 | 2022 | 1889 | 0.220 |
Why?
|
Education, Medical, Graduate | 1 | 2014 | 2205 | 0.210 |
Why?
|
Delivery of Health Care | 2 | 2022 | 4849 | 0.210 |
Why?
|
Nerve Sheath Neoplasms | 1 | 2023 | 194 | 0.210 |
Why?
|
Antigens, CD19 | 2 | 2022 | 348 | 0.200 |
Why?
|
Medical Oncology | 3 | 2022 | 2114 | 0.190 |
Why?
|
Receptor, erbB-3 | 1 | 2020 | 126 | 0.190 |
Why?
|
Neuregulin-1 | 1 | 2020 | 141 | 0.190 |
Why?
|
Autocrine Communication | 1 | 2020 | 178 | 0.190 |
Why?
|
Clinical Competence | 1 | 2016 | 4646 | 0.190 |
Why?
|
Whole Body Imaging | 2 | 2020 | 281 | 0.190 |
Why?
|
Anticonvulsants | 2 | 2019 | 1854 | 0.180 |
Why?
|
Receptors, Eph Family | 1 | 2018 | 48 | 0.170 |
Why?
|
Adult | 26 | 2022 | 212129 | 0.170 |
Why?
|
Cyanides | 1 | 2018 | 89 | 0.170 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2020 | 2119 | 0.170 |
Why?
|
Receptor, IGF Type 1 | 1 | 2020 | 403 | 0.170 |
Why?
|
Magnetic Resonance Imaging | 7 | 2023 | 34394 | 0.170 |
Why?
|
Guanidines | 1 | 2018 | 206 | 0.160 |
Why?
|
Quality of Life | 5 | 2022 | 11691 | 0.160 |
Why?
|
Neoplasm Proteins | 2 | 2021 | 3777 | 0.150 |
Why?
|
Videoconferencing | 1 | 2019 | 190 | 0.150 |
Why?
|
Male | 28 | 2022 | 351081 | 0.150 |
Why?
|
Radiation Oncology | 1 | 2022 | 510 | 0.150 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2021 | 1394 | 0.150 |
Why?
|
Follow-Up Studies | 6 | 2022 | 39285 | 0.140 |
Why?
|
Mind-Body Therapies | 1 | 2019 | 248 | 0.140 |
Why?
|
Health Literacy | 2 | 2017 | 391 | 0.140 |
Why?
|
Radiosurgery | 2 | 2022 | 1349 | 0.140 |
Why?
|
Antineoplastic Agents | 4 | 2020 | 13732 | 0.140 |
Why?
|
Focus Groups | 1 | 2020 | 1247 | 0.140 |
Why?
|
Deafness | 1 | 2019 | 431 | 0.140 |
Why?
|
Psychotherapy, Group | 1 | 2019 | 407 | 0.140 |
Why?
|
Mutation | 5 | 2021 | 29442 | 0.140 |
Why?
|
Female | 27 | 2022 | 377334 | 0.140 |
Why?
|
Neurotoxicity Syndromes | 1 | 2019 | 267 | 0.140 |
Why?
|
Critical Pathways | 1 | 2019 | 459 | 0.140 |
Why?
|
Cerebral Ventricle Neoplasms | 1 | 2014 | 45 | 0.130 |
Why?
|
Genetic Association Studies | 3 | 2020 | 2720 | 0.130 |
Why?
|
Steroids | 1 | 2019 | 886 | 0.120 |
Why?
|
Lateral Ventricles | 1 | 2014 | 140 | 0.120 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2007 | 3050 | 0.120 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2022 | 2496 | 0.120 |
Why?
|
DNA Repeat Expansion | 1 | 2012 | 63 | 0.110 |
Why?
|
Iron-Binding Proteins | 1 | 2012 | 81 | 0.110 |
Why?
|
Middle Aged | 18 | 2022 | 214871 | 0.110 |
Why?
|
SEER Program | 1 | 2018 | 1576 | 0.110 |
Why?
|
Immediate-Early Proteins | 1 | 2015 | 457 | 0.110 |
Why?
|
Hearing Loss | 1 | 2019 | 711 | 0.110 |
Why?
|
Osteoarthritis, Knee | 1 | 2022 | 1221 | 0.110 |
Why?
|
Survival Rate | 2 | 2018 | 13255 | 0.110 |
Why?
|
Patient Care | 1 | 2018 | 614 | 0.110 |
Why?
|
Stereotaxic Techniques | 1 | 2014 | 560 | 0.110 |
Why?
|
Tumor Burden | 1 | 2018 | 1914 | 0.110 |
Why?
|
Pain Measurement | 2 | 2022 | 3509 | 0.110 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2015 | 651 | 0.100 |
Why?
|
Practice Guidelines as Topic | 2 | 2019 | 7480 | 0.100 |
Why?
|
Education, Medical, Undergraduate | 1 | 2020 | 997 | 0.100 |
Why?
|
Aged | 13 | 2022 | 162674 | 0.100 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2021 | 1942 | 0.100 |
Why?
|
Integrins | 1 | 2015 | 833 | 0.100 |
Why?
|
Young Adult | 10 | 2022 | 56155 | 0.100 |
Why?
|
Biopsy, Needle | 1 | 2015 | 1679 | 0.100 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2015 | 1838 | 0.100 |
Why?
|
DNA Methylation | 2 | 2023 | 4085 | 0.100 |
Why?
|
Anti-Retroviral Agents | 1 | 2019 | 1583 | 0.090 |
Why?
|
Adrenal Cortex Hormones | 1 | 2019 | 1847 | 0.090 |
Why?
|
Evoked Potentials, Motor | 1 | 2012 | 431 | 0.090 |
Why?
|
Corpus Callosum | 1 | 2014 | 731 | 0.090 |
Why?
|
Communication | 2 | 2020 | 3498 | 0.090 |
Why?
|
Cerebrovascular Disorders | 1 | 2015 | 1512 | 0.090 |
Why?
|
Topotecan | 1 | 2008 | 136 | 0.090 |
Why?
|
Patient Satisfaction | 2 | 2021 | 3396 | 0.080 |
Why?
|
Tyrphostins | 1 | 2007 | 71 | 0.080 |
Why?
|
Atrophy | 1 | 2012 | 1506 | 0.080 |
Why?
|
Chemokine CCL22 | 1 | 2007 | 25 | 0.080 |
Why?
|
Geriatric Assessment | 1 | 2015 | 1320 | 0.080 |
Why?
|
Prognosis | 5 | 2020 | 29168 | 0.080 |
Why?
|
Treatment Outcome | 7 | 2022 | 62186 | 0.080 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 2 | 2021 | 622 | 0.080 |
Why?
|
Methotrexate | 1 | 2014 | 1723 | 0.080 |
Why?
|
Carmustine | 1 | 2007 | 144 | 0.080 |
Why?
|
Receptors, CCR4 | 1 | 2007 | 81 | 0.080 |
Why?
|
United States | 6 | 2022 | 67665 | 0.080 |
Why?
|
Schools, Medical | 1 | 2014 | 882 | 0.080 |
Why?
|
Genotype | 2 | 2020 | 12921 | 0.080 |
Why?
|
Telemedicine | 2 | 2021 | 2612 | 0.080 |
Why?
|
Ambulatory Care | 1 | 2018 | 2773 | 0.080 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2015 | 3555 | 0.080 |
Why?
|
Internal Medicine | 1 | 2014 | 1006 | 0.080 |
Why?
|
Receptors, CCR2 | 1 | 2007 | 220 | 0.070 |
Why?
|
Positron-Emission Tomography | 1 | 2023 | 6230 | 0.070 |
Why?
|
Protein Kinase Inhibitors | 3 | 2021 | 5482 | 0.070 |
Why?
|
Sequence Analysis, DNA | 1 | 2017 | 4910 | 0.070 |
Why?
|
Societies, Medical | 1 | 2018 | 3769 | 0.070 |
Why?
|
Cerebellum | 1 | 2012 | 1491 | 0.070 |
Why?
|
Morpholines | 2 | 2020 | 571 | 0.070 |
Why?
|
Cost-Benefit Analysis | 1 | 2017 | 5258 | 0.070 |
Why?
|
Population Surveillance | 1 | 2015 | 2631 | 0.070 |
Why?
|
Disease-Free Survival | 1 | 2015 | 7051 | 0.070 |
Why?
|
Chemokine CCL2 | 1 | 2007 | 659 | 0.070 |
Why?
|
Angiogenesis Inhibitors | 1 | 2014 | 2075 | 0.060 |
Why?
|
Neurosurgical Procedures | 1 | 2015 | 2032 | 0.060 |
Why?
|
Dacarbazine | 1 | 2007 | 588 | 0.060 |
Why?
|
Cross-Sectional Studies | 2 | 2022 | 23283 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2021 | 9561 | 0.060 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2015 | 3502 | 0.060 |
Why?
|
Child | 5 | 2022 | 74146 | 0.060 |
Why?
|
STAT3 Transcription Factor | 1 | 2007 | 905 | 0.060 |
Why?
|
Disease Management | 3 | 2019 | 2534 | 0.060 |
Why?
|
Cell Line, Tumor | 4 | 2020 | 16943 | 0.060 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 11317 | 0.060 |
Why?
|
Mice, SCID | 2 | 2018 | 2842 | 0.060 |
Why?
|
Retrospective Studies | 6 | 2022 | 72255 | 0.060 |
Why?
|
Adolescent | 5 | 2022 | 84999 | 0.060 |
Why?
|
Benzamides | 2 | 2020 | 1411 | 0.060 |
Why?
|
Cytoplasm | 1 | 2007 | 1636 | 0.060 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2020 | 8925 | 0.050 |
Why?
|
Societies | 1 | 2022 | 98 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2018 | 8674 | 0.050 |
Why?
|
Immunohistochemistry | 1 | 2015 | 11766 | 0.050 |
Why?
|
Genomics | 3 | 2023 | 5333 | 0.050 |
Why?
|
Prospective Studies | 2 | 2022 | 51181 | 0.050 |
Why?
|
Receptor, EphA2 | 1 | 2020 | 44 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2018 | 5010 | 0.050 |
Why?
|
Immunosuppressive Agents | 1 | 2014 | 4208 | 0.050 |
Why?
|
Age Factors | 1 | 2018 | 18789 | 0.050 |
Why?
|
Cerebrospinal Fluid Proteins | 1 | 2020 | 57 | 0.050 |
Why?
|
Benzoxazoles | 1 | 2020 | 86 | 0.050 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2018 | 3694 | 0.050 |
Why?
|
Cognition Disorders | 1 | 2014 | 3987 | 0.050 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 3970 | 0.050 |
Why?
|
Flow Cytometry | 2 | 2008 | 6137 | 0.050 |
Why?
|
Cranial Irradiation | 1 | 2022 | 441 | 0.040 |
Why?
|
Triazines | 1 | 2020 | 310 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2022 | 11285 | 0.040 |
Why?
|
Algorithms | 1 | 2019 | 13669 | 0.040 |
Why?
|
Cohort Studies | 2 | 2019 | 39804 | 0.040 |
Why?
|
Risk Assessment | 2 | 2021 | 23511 | 0.040 |
Why?
|
Dura Mater | 1 | 2020 | 294 | 0.040 |
Why?
|
Photography | 1 | 2021 | 531 | 0.040 |
Why?
|
Organizations, Nonprofit | 1 | 2018 | 117 | 0.040 |
Why?
|
Workflow | 1 | 2022 | 812 | 0.040 |
Why?
|
Transcription Factors | 1 | 2018 | 12047 | 0.040 |
Why?
|
Aged, 80 and over | 3 | 2019 | 58505 | 0.040 |
Why?
|
Self Report | 2 | 2018 | 3420 | 0.040 |
Why?
|
Genetic Heterogeneity | 1 | 2020 | 751 | 0.040 |
Why?
|
Trust | 1 | 2020 | 485 | 0.040 |
Why?
|
Brain | 1 | 2023 | 25188 | 0.040 |
Why?
|
Pyrimidines | 2 | 2020 | 2969 | 0.040 |
Why?
|
Disease Progression | 1 | 2012 | 13302 | 0.040 |
Why?
|
Single-Blind Method | 1 | 2019 | 1594 | 0.030 |
Why?
|
Pyridines | 1 | 2007 | 2867 | 0.030 |
Why?
|
Analgesics | 1 | 2022 | 1022 | 0.030 |
Why?
|
Lung | 1 | 2014 | 9765 | 0.030 |
Why?
|
Drug Monitoring | 1 | 2020 | 935 | 0.030 |
Why?
|
Factor Analysis, Statistical | 1 | 2017 | 995 | 0.030 |
Why?
|
Neoplasms | 1 | 2022 | 20515 | 0.030 |
Why?
|
Sequence Deletion | 1 | 2018 | 1546 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2018 | 1923 | 0.030 |
Why?
|
HIV Infections | 1 | 2019 | 15616 | 0.030 |
Why?
|
Automobile Driving | 1 | 2018 | 408 | 0.030 |
Why?
|
T-Lymphocytes | 2 | 2008 | 10379 | 0.030 |
Why?
|
Cell Proliferation | 2 | 2020 | 10800 | 0.030 |
Why?
|
Sirolimus | 1 | 2020 | 1573 | 0.030 |
Why?
|
Immunotherapy | 1 | 2008 | 4118 | 0.030 |
Why?
|
Consensus | 1 | 2021 | 2744 | 0.030 |
Why?
|
Histones | 1 | 2023 | 2580 | 0.030 |
Why?
|
Travel | 1 | 2018 | 739 | 0.030 |
Why?
|
Age Distribution | 1 | 2018 | 2927 | 0.030 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 2266 | 0.030 |
Why?
|
Ambulatory Care Facilities | 1 | 2018 | 888 | 0.030 |
Why?
|
Clinical Trials as Topic | 2 | 2021 | 8016 | 0.030 |
Why?
|
Qualitative Research | 1 | 2020 | 2534 | 0.030 |
Why?
|
Phenotype | 2 | 2020 | 16371 | 0.030 |
Why?
|
World Health Organization | 1 | 2017 | 1278 | 0.030 |
Why?
|
Immunoblotting | 1 | 2015 | 1790 | 0.030 |
Why?
|
Heterozygote | 1 | 2018 | 2791 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2020 | 2592 | 0.030 |
Why?
|
Biological Products | 1 | 2019 | 834 | 0.020 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2019 | 1875 | 0.020 |
Why?
|
International Classification of Diseases | 1 | 2015 | 853 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2015 | 1725 | 0.020 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 1468 | 0.020 |
Why?
|
Pyrazoles | 1 | 2020 | 1974 | 0.020 |
Why?
|
Educational Measurement | 1 | 2017 | 1279 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2018 | 6566 | 0.020 |
Why?
|
Activities of Daily Living | 1 | 2019 | 2325 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2021 | 3701 | 0.020 |
Why?
|
Genetic Testing | 1 | 2022 | 3319 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2019 | 4916 | 0.020 |
Why?
|
Mutation, Missense | 1 | 2018 | 2500 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2020 | 6779 | 0.020 |
Why?
|
Residence Characteristics | 1 | 2018 | 1979 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2022 | 11900 | 0.020 |
Why?
|
Base Sequence | 1 | 2020 | 13315 | 0.020 |
Why?
|
Cell Movement | 1 | 2020 | 5468 | 0.020 |
Why?
|
ZAP-70 Protein-Tyrosine Kinase | 1 | 2007 | 70 | 0.020 |
Why?
|
Fas Ligand Protein | 1 | 2008 | 227 | 0.020 |
Why?
|
Signal Transduction | 3 | 2020 | 23973 | 0.020 |
Why?
|
Computational Biology | 1 | 2020 | 3557 | 0.020 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 2008 | 321 | 0.020 |
Why?
|
Proteomics | 1 | 2020 | 3256 | 0.020 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2019 | 2085 | 0.020 |
Why?
|
Drug Delivery Systems | 1 | 2018 | 2234 | 0.020 |
Why?
|
Biopsy | 1 | 2019 | 6750 | 0.020 |
Why?
|
Child, Preschool | 2 | 2019 | 41181 | 0.020 |
Why?
|
Hospitals | 1 | 2019 | 3331 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2015 | 6290 | 0.020 |
Why?
|
Mice | 3 | 2018 | 80995 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2017 | 7722 | 0.020 |
Why?
|
Liver Neoplasms | 1 | 2019 | 4091 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2021 | 19499 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2020 | 8998 | 0.010 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2015 | 3695 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2019 | 4230 | 0.010 |
Why?
|
Adjuvants, Immunologic | 1 | 2007 | 977 | 0.010 |
Why?
|
Risk Factors | 2 | 2021 | 70704 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2020 | 12425 | 0.010 |
Why?
|
Apoptosis | 1 | 2018 | 10112 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 7213 | 0.010 |
Why?
|
Leukocytes, Mononuclear | 1 | 2007 | 1734 | 0.010 |
Why?
|
Mice, Nude | 1 | 2007 | 3825 | 0.010 |
Why?
|
Interferon-gamma | 1 | 2008 | 3251 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2019 | 7481 | 0.010 |
Why?
|
Animals | 3 | 2018 | 170726 | 0.010 |
Why?
|
Up-Regulation | 1 | 2008 | 4353 | 0.010 |
Why?
|
Immune Tolerance | 1 | 2007 | 2332 | 0.010 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2007 | 2480 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2015 | 21790 | 0.010 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2007 | 3007 | 0.010 |
Why?
|
Infant | 1 | 2018 | 34497 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2018 | 17395 | 0.010 |
Why?
|
Hospitalization | 1 | 2015 | 9718 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 2007 | 5897 | 0.010 |
Why?
|
Phosphorylation | 1 | 2007 | 8738 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2019 | 20398 | 0.010 |
Why?
|